Phase II Study of Amivantamab in EGFR or MET- Amplified Esophagogastric Cancer
Latest Information Update: 08 Mar 2024
At a glance
- Drugs Amivantamab (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 04 Oct 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2025.
- 04 Oct 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2025.
- 02 Dec 2021 Status changed from not yet recruiting to recruiting.